Clinical characteristics in SIT Trial participants and an independent cohort of children with sickle cell anemia
| . | SIT Trial participants . | . | ||
|---|---|---|---|---|
| . | Silent cerebral infarcts (n = 286) . | Overt infarct (n = 13)* . | Silent cerebral infarcts with recurrent silent or overt infarct at 3-y follow-up (n = 20)† . | Independent SCA cohort for cerebral blood flow analysis (n = 41) . |
| Age, y | 9.3 (2.5) | 8.5 (2.4) | 8.0 (2.0) | 10.8 (3.9) |
| Sex, male | 128 (44%) | 5 (38%) | 12 (60%) | 21 (51%) |
| Race, African | 281 (98%) | 13 (100%) | 20 (100%) | 41 (100%) |
| Hemoglobin, g/dL | 8.0 (1.0) | 7.7 (0.9) | 7.9 (1.1) | 8.5 (1.2) |
| Hemoglobin, F % | 11 (9) | 9 (4) | 13 (8) | 18 (10) |
| Hemoglobin, S % | 84 (11) | 81 (21) | 84 (8) | 76 (11) |
| White blood cell count ×106/µL | 13.2 (7.8) | 10.2 (4.3) | 13.7 (4.9) | 10.0 (2.6) |
| Reticulocyte, % | 12.8 (5.6) | 13.2 (4.6) | 13.7 (5.9) | — |
| SpO2% | 96.1 (3.0) | 96.3 (2.4) | 96.5 (2.5) | 96.7 (2.7) |
| Systolic BP, mm Hg | 109 (11) | 108 (11) | 106 (12) | — |
| . | SIT Trial participants . | . | ||
|---|---|---|---|---|
| . | Silent cerebral infarcts (n = 286) . | Overt infarct (n = 13)* . | Silent cerebral infarcts with recurrent silent or overt infarct at 3-y follow-up (n = 20)† . | Independent SCA cohort for cerebral blood flow analysis (n = 41) . |
| Age, y | 9.3 (2.5) | 8.5 (2.4) | 8.0 (2.0) | 10.8 (3.9) |
| Sex, male | 128 (44%) | 5 (38%) | 12 (60%) | 21 (51%) |
| Race, African | 281 (98%) | 13 (100%) | 20 (100%) | 41 (100%) |
| Hemoglobin, g/dL | 8.0 (1.0) | 7.7 (0.9) | 7.9 (1.1) | 8.5 (1.2) |
| Hemoglobin, F % | 11 (9) | 9 (4) | 13 (8) | 18 (10) |
| Hemoglobin, S % | 84 (11) | 81 (21) | 84 (8) | 76 (11) |
| White blood cell count ×106/µL | 13.2 (7.8) | 10.2 (4.3) | 13.7 (4.9) | 10.0 (2.6) |
| Reticulocyte, % | 12.8 (5.6) | 13.2 (4.6) | 13.7 (5.9) | — |
| SpO2% | 96.1 (3.0) | 96.3 (2.4) | 96.5 (2.5) | 96.7 (2.7) |
| Systolic BP, mm Hg | 109 (11) | 108 (11) | 106 (12) | — |
The table shows clinical characteristics of SIT Trial participants with (1) silent cerebral infarcts detected on screening, (2) overt infarcts detected on screening and not randomly allocated, and (3) silent cerebral infarcts detected on screening who were followed prospectively and subsequently developed recurrent silent cerebral infarcts or strokes. Clinical characteristics of an independent cohort of children with sickle cell anemia, including those with and without silent cerebral infarcts and who had cerebral blood flow assessment (non-SIT Trial participants), are also shown.
Data shown as mean (standard deviation) for continuous variables and N (%) for dichotomous variable.
F, fetal; S, sickle.
SIT Trial participants, screened only (not enrolled in the trial), followed prospectively and determined to have strokes.
SIT Trial participants enrolled in the randomized control trial.